

Group 1771



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The Commissioner for Patents, Washington, D.C. 20231 on

May 17, 2000

Julia A. Glazer 41,783  
Name of Attorney Registration No.

  
Signature of Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

7  
330 AM

IN RE APPLICATION OF:  
Francis James Rourke et al. :  
SERIAL NO.: 09/188,442 : GROUP ART UNIT: 1771  
FILED: November 9, 1998 : EXAMINER: N.L. TORRES-VELAZQUEZ  
FOR: Disposable Premoistened  
Wipe Containing An Antimicrobial  
Protease Inhibitor :  
P&G CASE: 7334 :

**RESPONSE TO OFFICE ACTION DATED FEBRUARY 17, 2000**

The Commissioner for Patents  
Washington, D.C. 20231

TC 1700 MAIL ROOM

RECEIVED  
MAY 25 2000

Dear Sir:

**REMARKS**

Applicants gratefully acknowledge the Examiner's finding of allowable subject matter in Claims 4, 6, 13, and 14.

**Election:**

The Examiner indicates that election is required in the instant application between Claims 1 - 16 (product) and Claims 17-20 (method of use). Applicants elect with traverse product Claims 1 - 16. The Examiner has based the restriction requirement on the supposition that the premoistened wipe of the instant invention can be used in a materially different process. The example the Examiner provides is the use of the premoistened wipe as a transdermal delivery system.

Applicants respectfully disagree. A transdermal delivery system requires percutaneous or systemic delivery (i.e.; requires a material to be absorbed into the bloodstream). This is totally the opposite purpose of the present invention. The purpose of the present invention is to solve a problem which occurs topically on the skin (i.e.; deliver a topical benefit to the skin in order to prevent the formation of diaper dermatitis on the skin). [See Instant Application page 2, lines 12 - 28] This purpose is accomplished via topical delivery to the skin and not via absorption into the bloodstream.